Skip to main content
. 2022 Feb 11;13:797438. doi: 10.3389/fendo.2022.797438

Table 1.

Participant demographic data.

Grouping Cpepund Cpephigh Non-diabetes Control
N 11 10 11
Male/Female 5/6 5/5 5/6
Age (Years) 39.64 ± 11.24 36.30 ± 11.11 38.00 ± 12.06
HbA1c (mmol/mol) 60.64 ± 9.96 56.50 ± 10.00 33.18 ± 1.99 *†
(%) 7.7 ± 0.9 7.3 ± 0.9 5.2 ± 0.2 *†
BMI (kg/m2) 25.66 ± 3.26 25.66 ± 4.05 25.55 ± 4.38
V˙O2peak (ml/kg/min) 35.23 ± 7.90 38.06 ± 10.22 37.26 ± 9.64
Cholesterol (mmol/L) 4.5 ± 1.1 4.0 ± 0.7 4.8 ± 0.8
HDL Cholesterol (mmol/L) 1.7 ± 0.4 1.5 ± 0.3 1.5 ± 0.4
Triglycerides(mmol/L) 0.8 ± 0.2 0.7 ± 0.3 1.1 ± 0.5
Age At Diagnosis 13.27 ± 4.50 25.10 ± 8.20 * -
Range (Years) 8 to 24 13 to 35
Duration Of Diabetes 26.18 ± 13.91 11.40 ± 6.45 * -
Range (Years) 10 to 47 3 to 20
Method Of Control (MDI/CSII) 5/6 6/4 -

Data presented as mean ± SD. * represents a significant differences compared to Cpepund, represents a significant differences compared to Cpephigh. P value from one-way ANOVA and independent samples t-test.